Lorna Charles

Appearances

LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
Date
May 9, 2023
BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…
Presenter
Maria T. Abreu
University of Miami Miller School of Medicine
Speakers
Silvio Danese
Douglas Wolf
James Canavan
Anjali Jain
Hsiuanlin Wu
AnnKatrin Petersen
Lorna Charles
Anita Afzali
Remo Panaccione